Table 4 Impact of COVID-19 on VL cases
Characteristics | Numbers (n = 66) (%) |
|---|---|
Place of diagnosis | |
Private hospitals | 5 (7.6) |
Government hospitals | 61 (92.4) |
Drugs used for treatment | |
Amphotericin_B | 1 (1.5) |
Liposomal_amphotericin B | 55 (83.3) |
Miltefosine | 8 (12.1) |
Combination therapy | 2 (3.1) |
Time taken to fall ill and seek treatment | |
1 week | 32 (48.5) |
2 weeks | 14 (21.2) |
3 weeks | 5 (7.6) |
4 weeks and more | 15 (22.7) |
Time taken for diagnosis | |
1 week | 45 (68.2) |
2 weeks | 7 (10.6) |
3 weeks | 4 (6.1) |
4 weeks and more | 10 (15.1) |
Time taken to start treatment | |
1 week | 65 (98.5) |
2 weeks | 1 (1.5) |
Appointment cancelled due to COVID-19 | |
Yes | 7 (10.6) |
No | 59 (89.4) |
Reasons for cancellation (multiple responses) | |
Lack of money | 3 (42.8) |
Fear of COVID-19 | 3 (42.8) |
Unavailability of transportation | 1 (14.3) |
Doctors did not give appointment | 1 (14.3) |
Shortage of drugs and treatment | |
Yes | 17 (25.7) |
No | 49 (74.2) |